Bleb Vascularity Clinical Trial
Official title:
Subconjunctival Bevacizumab Injection for the Prevention of Bleb Vascularization Post Trabeculectomy
Trabeculectomy is an ocular surgery intended to reduce intra-ocular pressure the surgery
creates a sub-conjunctival filtering bleb which filters aqueous humor fluid out.
A rather common adverse event of the surgery is increasing vascularity of the conjunctiva
overlying the bleb. This leads to adherence of the conjunctiva to the sclera and fibrosis
and finally failure of the bleb (and of the surgery) this study intends to demonstrate that
post operative subconjunctival bevacizumab injection will reduce incidence of bleb
vascularity and ultimately, bleb failure.
trabeculectomy is an ocular surgery intended to reduce intra-ocular pressure the surgery
creates a sub-conjunctival filtering bleb which filters aqueous humor fluid out.
a rather common adverse event of the surgery is increasing vascularity of the conjunctiva
overlying the bleb. this leads to adherence of the conjunctiva to the sclera and fibrosis
and finally failure of the bleb (and of the surgery) this study wishes to demonstrate that
post operative subconjunctival bevacizumab injection will reduce incidence of bleb
vascularity and ultimately, bleb failure.
during the study, one study group will be given subconjunctival bevacizumab 1 week after
surgery, another study group will be given subconjunctival bevacizumab 2 week after surgery,
and a third group will serve as control and will not receive bevacizumab. if bleb
vascularity will be diagnosed all patients will be treated according to current guidelines.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00815594 -
Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
|
Phase 4 |